PMID- 16385925
OWN - NLM
STAT- MEDLINE
DCOM- 20060126
LR  - 20170511
IS  - 0001-5385 (Print)
IS  - 0001-5385 (Linking)
VI  - 60
IP  - 6
DP  - 2005 Dec
TI  - The association between NT-proBNP levels, functional capacity and stage in 
      patients with heart failure.
PG  - 631-8
AB  - OBJECTIVE: Amino-terminal probrain natriuretic peptide (NT-proBNP), a 
      biologically inactive derivative of BNP, is clinically more useful owing to its 
      longer half-life, higher plasma concentrations, lesser variation among 
      individuals, and higher in vitro stability. In this regard, NT-proBNP may be a 
      better indicator of the severity of ventricular dysfunction. In this study, the 
      association of NT-proBNP levels with functional capacity and stage of heart 
      failure was explored in patients with CHF. Also, we particularly focused on the 
      presence and significance of neurohormonal activation in the group of patients 
      classified as stage-A according to ACC/AHA guidelines. METHODS AND RESULTS: 64 
      patients with CHF (31 men, 33 women; mean age 58.26 +/- 10.59 y) and 36 healthy 
      controls (24 men, 12 women; mean age 57.47 +/- 10.83) were included in this 
      study. The New York Heart Association (NYHA) classification system (I, II, III, 
      IV) was used to define the functional capacity; and the stage of the heart 
      failure was based on the ACC/AHA guidelines (A, B, C, D). Healthy female 
      participants had higher NT-proBNP levels compared to their male counterparts (p < 
      0.001). Left ventricular ejection fraction (LVEF) did not correlate significantly 
      with functional capacity and stage of the disease. CHF patients had higher 
      NT-proBNP compared to controls (p < 0.001). There was a positive correlation 
      between NT-proBNP and functional capacity in patients, and NT-proBNP increased 
      significantly with each increasing class of the disease. Similarly, a positive 
      correlation existed between the stage of heart failure and NT-proBNP levels, 
      which increased significantly with increasing stages of the disease. Patients 
      with NYHA I and stage A disease had higher NT-proBNP levels compared to controls 
      (p = 0.04). CONCLUSIONS: The severity of CHF can be objectively assessed by 
      measuring the circulating levels of NT-proBNP. Even in NYHA I and stage A 
      disease, NT-proBNP levels are higher compared to controls (p = 0.04). NT-proBNP 
      can provide objective information regarding the severity of the disease and also 
      aid in treatment decisions in patients with CHF.
FAU - Karabulut, Aziz
AU  - Karabulut A
AD  - Dicle University School of Medicine, Department of Cardiology, Diyarbakir, 
      Turkey. azkar@dicle.edu.tr
FAU - Kaplan, Abdurrahman
AU  - Kaplan A
FAU - Aslan, Cetin
AU  - Aslan C
FAU - Iltumur, Kenan
AU  - Iltumur K
FAU - Toprak, Gulten
AU  - Toprak G
FAU - Toprak, Nizamettin
AU  - Toprak N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Female
MH  - Heart Failure/blood/*diagnosis/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Predictive Value of Tests
MH  - Probability
MH  - Radioimmunoassay
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Survival Rate
MH  - Ventricular Dysfunction, Left/blood/*diagnosis/*mortality
EDAT- 2006/01/03 09:00
MHDA- 2006/01/27 09:00
CRDT- 2006/01/03 09:00
PHST- 2006/01/03 09:00 [pubmed]
PHST- 2006/01/27 09:00 [medline]
PHST- 2006/01/03 09:00 [entrez]
AID - 10.2143/AC.60.6.2004936 [doi]
PST - ppublish
SO  - Acta Cardiol. 2005 Dec;60(6):631-8. doi: 10.2143/AC.60.6.2004936.